X0508 4 2026-01-30 0 0001867096 Xeris Biopharma Holdings, Inc. XERS 0002031695 McCulloch Kevin C/O XERIS BIOPHARMA HOLDINGS, INC. 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 0 1 0 0 See Remarks 0 Common Stock 2026-01-30 4 A 0 168463 0 A 1853889 D Common Stock 2026-01-31 4 F 0 68454 7.36 D 1785435 D Common Stock 2026-01-31 4 F 0 30289 7.36 D 1755146 D Common Stock 2026-01-31 4 F 0 27319 7.36 D 1727827 D Common Stock 25000 I By Spouse Stock Option (Right to Buy) 7.36 2026-01-30 4 A 0 225225 0 A 2036-01-30 Common Stock 225225 225225 D These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date. President and Chief Operating Officer /s/ Beth Hecht, Attorney-in-Fact 2026-02-02